Company Description
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.
The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products.
This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings.
The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
| Country | United States |
| Founded | 1969 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 63,000 |
| CEO | Rainer M. Blair |
Contact Details
Address: 2200 Pennsylvania Ave. N.w., Suite 800w Washington, District of Columbia 20037-1701 United States | |
| Phone | (202) 828-0850 |
| Website | danaher.com |
Stock Details
| Ticker Symbol | DHR |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000313616 |
| CUSIP Number | 235851102 |
| ISIN Number | US2358511028 |
| Employer ID | 59-1995548 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Steven M. Rales | Co-Founder and Chairman |
| Rainer M. Blair | President, Chief Executive Officer and Director |
| Mitchell P. Rales | Co-Founder and Director |
| Matthew R. McGrew | Chief Financial Officer and Executive Vice President |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Senior Vice President and Chief Science Officer |
| Georgeann F. Couchara | Senior Vice President of Human Resources |
| Joakim Weidemanis | Executive Vice President |
| Christopher M. Bouda | Vice President and Chief Accounting Officer |
| John Bedford | Vice President of Investor Relations |
| Brian W. Ellis | Senior Vice President, General Counsel and Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Apr 1, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Apr 1, 2024 | 25-NSE | Filing |
| Mar 27, 2024 | ARS | Filing |
| Mar 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 26, 2024 | 144 | Filing |
| Feb 21, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Feb 21, 2024 | 10-K | Annual Report |
| Feb 15, 2024 | 144/A | Filing |